Published: Jul 18, 2024, 05:30 IST | Updated: Jul 18, 2024, 05:30 IST
Shares of Novo Nordisk and Eli Lilly dropped on Wednesday following the release of promising early-stage trial data from Roche's new obesity drug candidate. Roche announced that its experimental once-daily pill showed an average weight loss of 6.1% over four weeks.